A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Genmab
Arcus Biosciences, Inc.
Pfizer
Pfizer
AstraZeneca
Fudan University
Tyligand Pharmaceuticals (Suzhou) Limited
M.D. Anderson Cancer Center
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hansoh BioMedical R&D Company
ImmunityBio, Inc.
ImmunityBio, Inc.
Taiho Pharmaceutical Co., Ltd.
Rutgers, The State University of New Jersey
Canadian Cancer Trials Group
Cantargia AB
University of California, San Francisco
Northwestern University
Incyte Corporation
Tarveda Therapeutics
AstraZeneca
Gilead Sciences
Western Regional Medical Center
Ziekenhuis Oost-Limburg
National Institutes of Health Clinical Center (CC)
Valerio Therapeutics
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Galectin Therapeutics Inc.